Antimicrobial resistance (AMR) poses a significant threat in the context of communicable diseases, challenging our ability to effectively treat infections caused by bacteria, viruses, parasites, and fungi. This global health concern arises when microorganisms evolve and become resistant to the drugs designed to combat them. In the realm of communicable diseases, bacteria are a major focus of concern due to their adaptability. Overuse and misuse of antimicrobial agents, such as antibiotics, contribute to the development of resistant strains. When infections become resistant to commonly prescribed medications, the effectiveness of treatment diminishes, leading to prolonged illnesses, increased healthcare costs, and a higher risk of spread within communities. Preventing and addressing antimicrobial resistance requires a multifaceted approach. This includes promoting responsible use of antimicrobial agents, improving diagnostic capabilities to ensure accurate prescriptions, and investing in research for new treatments. Public awareness campaigns about the importance of completing prescribed courses of antibiotics and not self-medicating are vital components of this strategy. In conclusion, the emergence of antimicrobial resistance has profound implications for managing communicable diseases. It underscores the urgency of adopting prudent practices in the use of antimicrobial agents to preserve their effectiveness, ensuring that we can continue to effectively combat infectious diseases and protect public health.
Speaker lineup for this track will be announced soon.
Browse all speakers →Extensively Drug-Resistant (XDR) bacterial infections represent a growing global crisis with profound impacts on morbidity, mortality, and health system sustainability. These pathogens, resistant to…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Antimicrobial Resistance work, reviewed by the scientific committee.
Meet public health researchers, educators, and policy leaders from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Antimicrobial Resistance research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Antimicrobial Resistance track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Antimicrobial Resistance. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Antimicrobial Resistance are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IPHC 2027 is a hybrid conference — attend the Antimicrobial Resistance track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
